Here are some problems delayed billing present and how you can avoid them.
Cabozantinib/atezolizumab improves PFS, shows no significant OS benefit in mCRPC
According to the authors, data from the CONTACT-02 trial show that cabozantinib plus atezolizumab may benefit selected patients with mCRPC.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Darolutamide plus ADT shows rPFS benefit in mHSPC
According to the authors, “darolutamide significantly reduced the risk of radiological progression or death by 46%” (HR=0.54, 95% CI, 0.41-0.71, P < .0001).
Health policy in urology: 2024 AUA Advocacy Summit recap
In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.
Radium223, chemotherapy improves mCRPC quality of life in phase 2 RAPSON
New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC
New findings from the open-label SPLASH trial show patients with mCRPC achieved improved progression-free survival as well as response rates and antigen-specific reductions.
